Foss F - Search Results

1

Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy.

Ren J, Liao X, Lewis JM, Chang J, Qu R, Carlson KR, Foss F, Girardi M. Ren J, et al. Among authors: foss f. Nat Commun. 2024 Jan 15;15(1):519. doi: 10.1038/s41467-024-44786-2. Nat Commun. 2024. PMID: 38225288 Free PMC article.

2

Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations.

Ren J, Qu R, Rahman NT, Lewis JM, King ALO, Liao X, Mirza FN, Carlson KR, Huang Y, Gigante S, Evans B, Rajendran BK, Xu S, Wang G, Foss FM, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Ren J, et al. Blood Adv. 2023 Feb 14;7(3):445-457. doi: 10.1182/bloodadvances.2022008168. Blood Adv. 2023. PMID: 35947128 Free PMC article.

3

Mycosis Fungoides and Sezary Syndrome.

Foss FM, Girardi M. Foss FM, et al. Hematol Oncol Clin North Am. 2017 Apr;31(2):297-315. doi: 10.1016/j.hoc.2016.11.008. Hematol Oncol Clin North Am. 2017. PMID: 28340880 Review.

4

Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.

Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Cyrenne BM, et al. Blood. 2017 Nov 9;130(19):2073-2083. doi: 10.1182/blood-2017-06-792150. Epub 2017 Oct 2. Blood. 2017. PMID: 28972015 Free PMC article.

5

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.

Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. Kim SR, et al. Among authors: foss fm. Oncotarget. 2018 Jun 26;9(49):29193-29207. doi: 10.18632/oncotarget.25670. eCollection 2018 Jun 26. Oncotarget. 2018. PMID: 30018745 Free PMC article.

6

JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. Yumeen S, et al. Blood Adv. 2020 May 26;4(10):2213-2226. doi: 10.1182/bloodadvances.2020001756. Blood Adv. 2020. PMID: 32437546 Free PMC article.

7

Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development.

Mirza FN, Yumeen S, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Mirza FN, et al. J Invest Dermatol. 2021 Jan;141(1):217-221. doi: 10.1016/j.jid.2020.05.097. Epub 2020 Jun 12. J Invest Dermatol. 2021. PMID: 32534802 Free article. Review. No abstract available.

8

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma.

King ALO, Mirza FN, Lewis JM, Carlson KR, Huntington S, Foss FM, Girardi M. King ALO, et al. JAAD Case Rep. 2020 Dec 25;8:89-92. doi: 10.1016/j.jdcr.2020.12.025. eCollection 2021 Feb. JAAD Case Rep. 2020. PMID: 33537387 Free PMC article. No abstract available.

9

Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings.

King ALO, Mirza FN, Lewis JM, Umlauf S, Surovtseva Y, Carlson KR, Foss FM, Girardi M. King ALO, et al. J Invest Dermatol. 2022 Jan;142(1):254-257. doi: 10.1016/j.jid.2021.04.035. Epub 2021 Jul 19. J Invest Dermatol. 2022. PMID: 34293349 Free article. No abstract available.

10

Genomic landscape of cutaneous T cell lymphoma.

Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Choi J, et al. Nat Genet. 2015 Sep;47(9):1011-9. doi: 10.1038/ng.3356. Epub 2015 Jul 20. Nat Genet. 2015. PMID: 26192916 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

291 results

Search Page